vs
Aclarion, Inc.（ACON）与CareDx, Inc.（CDNA）财务数据对比。点击上方公司名可切换其他公司
CareDx, Inc.的季度营收约是Aclarion, Inc.的5865.7倍（$108.4M vs $18.5K）。CareDx, Inc.净利率更高（-3.8% vs -10223.7%，领先10219.9%）。Aclarion, Inc.同比增速更快（80.6% vs 25.2%）。过去两年Aclarion, Inc.的营收复合增速更高（35.2% vs 22.7%）
Aclarion, Inc.是一家专注于慢性下背痛诊疗的医疗科技企业，核心产品基于专利磁共振波谱技术，可精准识别患者的疼痛性椎间盘，服务美国市场的医疗机构与患者，业务覆盖慢性疼痛管理、脊柱护理两大核心领域。
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
ACON vs CDNA — 直观对比
营收规模更大
CDNA
是对方的5865.7倍
$18.5K
营收增速更快
ACON
高出55.4%
25.2%
净利率更高
CDNA
高出10219.9%
-10223.7%
两年增速更快
ACON
近两年复合增速
22.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $18.5K | $108.4M |
| 净利润 | $-1.9M | $-4.1M |
| 毛利率 | 9.7% | — |
| 营业利润率 | -10785.8% | -5.6% |
| 净利率 | -10223.7% | -3.8% |
| 营收同比 | 80.6% | 25.2% |
| 净利润同比 | 5.0% | -104.7% |
| 每股收益（稀释后） | $1.39 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACONCDNA
| Q4 25 | $18.5K | $108.4M | ||
| Q3 25 | $18.9K | $100.1M | ||
| Q2 25 | $19.3K | $86.7M | ||
| Q1 25 | $19.0K | $84.7M | ||
| Q4 24 | $10.2K | $86.6M | ||
| Q3 24 | $14.4K | $82.9M | ||
| Q2 24 | $11.0K | $92.3M | ||
| Q1 24 | $10.1K | $72.0M |
净利润ACONCDNA
| Q4 25 | $-1.9M | $-4.1M | ||
| Q3 25 | $-1.7M | $1.7M | ||
| Q2 25 | $-1.6M | $-8.6M | ||
| Q1 25 | $-2.0M | $-10.4M | ||
| Q4 24 | $-2.0M | $87.7M | ||
| Q3 24 | $-1.4M | $-10.6M | ||
| Q2 24 | $-1.2M | $-4.6M | ||
| Q1 24 | $-2.4M | $-19.9M |
毛利率ACONCDNA
| Q4 25 | 9.7% | — | ||
| Q3 25 | 23.2% | — | ||
| Q2 25 | 26.6% | — | ||
| Q1 25 | -23.6% | — | ||
| Q4 24 | -100.9% | — | ||
| Q3 24 | -48.1% | — | ||
| Q2 24 | -112.3% | — | ||
| Q1 24 | -92.6% | — |
营业利润率ACONCDNA
| Q4 25 | -10785.8% | -5.6% | ||
| Q3 25 | -9666.2% | -0.2% | ||
| Q2 25 | -8988.6% | -12.8% | ||
| Q1 25 | -7856.0% | -15.8% | ||
| Q4 24 | -17652.7% | 97.5% | ||
| Q3 24 | -8995.3% | -16.6% | ||
| Q2 24 | -10350.6% | -7.9% | ||
| Q1 24 | -12609.3% | -31.3% |
净利率ACONCDNA
| Q4 25 | -10223.7% | -3.8% | ||
| Q3 25 | -9008.0% | 1.7% | ||
| Q2 25 | -8285.9% | -9.9% | ||
| Q1 25 | -10728.4% | -12.2% | ||
| Q4 24 | -19444.6% | 101.3% | ||
| Q3 24 | -9482.7% | -12.8% | ||
| Q2 24 | -11285.0% | -5.0% | ||
| Q1 24 | -23720.6% | -27.6% |
每股收益（稀释后）ACONCDNA
| Q4 25 | $1.39 | $-0.08 | ||
| Q3 25 | $-2.93 | $0.03 | ||
| Q2 25 | $-2.75 | $-0.16 | ||
| Q1 25 | $-9.32 | $-0.19 | ||
| Q4 24 | $-809.36 | $1.60 | ||
| Q3 24 | $-1321.49 | $-0.20 | ||
| Q2 24 | $-1362.83 | $-0.09 | ||
| Q1 24 | $-3985.22 | $-0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.0M | $177.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.8M | $303.1M |
| 总资产 | $13.7M | $413.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACONCDNA
| Q4 25 | $12.0M | $177.2M | ||
| Q3 25 | $11.3M | $194.2M | ||
| Q2 25 | $12.8M | $186.3M | ||
| Q1 25 | $14.8M | $230.9M | ||
| Q4 24 | $453.7K | $260.7M | ||
| Q3 24 | $1.3M | $240.9M | ||
| Q2 24 | $1.2M | $228.9M | ||
| Q1 24 | $2.1M | $215.9M |
总债务ACONCDNA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | — |
股东权益ACONCDNA
| Q4 25 | $12.8M | $303.1M | ||
| Q3 25 | $12.5M | $311.1M | ||
| Q2 25 | $14.2M | $327.4M | ||
| Q1 25 | $15.8M | $379.3M | ||
| Q4 24 | $970.1K | $378.4M | ||
| Q3 24 | $2.5M | $273.2M | ||
| Q2 24 | $1.6M | $264.7M | ||
| Q1 24 | $2.5M | $256.2M |
总资产ACONCDNA
| Q4 25 | $13.7M | $413.2M | ||
| Q3 25 | $13.2M | $432.3M | ||
| Q2 25 | $14.8M | $444.3M | ||
| Q1 25 | $16.5M | $489.6M | ||
| Q4 24 | $2.1M | $491.1M | ||
| Q3 24 | $3.2M | $477.0M | ||
| Q2 24 | $3.1M | $466.8M | ||
| Q1 24 | $3.7M | $452.4M |
负债/权益比ACONCDNA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.6M | $21.4M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ACONCDNA
| Q4 25 | $-1.6M | $21.4M | ||
| Q3 25 | $-1.2M | $37.4M | ||
| Q2 25 | $-1.9M | $9.9M | ||
| Q1 25 | $-2.5M | $-26.6M | ||
| Q4 24 | $-922.9K | $21.9M | ||
| Q3 24 | $-1.1M | $12.5M | ||
| Q2 24 | $-1.1M | $18.9M | ||
| Q1 24 | $-2.2M | $-15.3M |
自由现金流ACONCDNA
| Q4 25 | — | — | ||
| Q3 25 | $-1.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率ACONCDNA
| Q4 25 | — | — | ||
| Q3 25 | -6164.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ACONCDNA
| Q4 25 | — | — | ||
| Q3 25 | 38.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率ACONCDNA
| Q4 25 | — | — | ||
| Q3 25 | — | 22.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACON
暂无分部数据
CDNA
| Services | $78.4M | 72% |
| Patient And Digital Solutions | $16.8M | 15% |
| Products | $13.3M | 12% |
